ArticleCancer cell2020
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.
Open access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.
- Bibliometric Analysis of ATAC-Seq and Its Use in Cancer Biology via Nucleic Acid Detection.Frontiers in medicine · 2020Pooled it
- Cryo-EM structure-based discovery of etravirine as a specific inhibitor of PRMT5/pICln protein-protein interaction for prostate cancer treatment.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- CRISPR decodes the RNA regulatory network in prostate cancer: A review from mechanisms to precision therapeutics.Non-coding RNA research · 2026Review
- ATP-dependent chromatin remodelers in prostate cancer progression and therapeutic resistance.Endocrinology · 2026Review
- A TBX2-HLX Regulatory Axis Is Associated with Advanced Prostate Cancer.Biomedicines · 2026Article
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- The Great Escape: the systems biology of endocrine resistance and lineage plasticity.Endocrine-related cancer · 2026Review
- CHD6 promotes triple-negative breast cancer progression and is associated with PI3K/AKT and MAPK pathways.International journal of clinical oncology · 2026Article
- Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis.Nature communications · 2026Article
- Review
- 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer.Endocrinology · 2026Review
- Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer.NPJ breast cancer · 2026Article
- GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Game of clones: decipher lineage plasticity in hormone-driven cancers.Cellular and molecular life sciences : CMLS · 2026Review
- Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.European urology · 2026Article
- Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer.Neoplasia (New York, N.Y.) · 2026Article
- Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.Journal of the National Cancer Center · 2026Review
- Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer.Journal of the National Cancer Center · 2026Review
- Identifying myosin heavy chain 11 as a predictive biomarker of prostate cancer progression and antiandrogen resistance.Oncology letters · 2026Article
- CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.Cell reports. Medicine · 2026Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 8 institutions in 1 country.
Zeda ZhangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chuanli ZhouDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Xiaoling LiDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Spencer D BarnesBioinformatics Core Facility of the Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Su DengDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Elizabeth HooverHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chi-Chao ChenCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA.
Young Sun LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Yanxiao ZhangLudwig Institute for Cancer Research, La Jolla, CA, USA.
Choushi WangDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Lauren A MetangDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Chao WuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Carla Rodriguez TiradoDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Nickolas A JohnsonDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
John WongvipatHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kristina NavrazhinaWeill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA.
Zhen CaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA.
Danielle ChoiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chun-Hao HuangCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA.
Eliot LintonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Xiaoping ChenDepartment of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Yupu LiangCenter for Clinical and Translational Science, Rockefeller University, New York, NY 10065, USA.
Christopher E MasonDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA; The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA; The WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, USA.
Elisa de StanchinaDepartment of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Wassim AbidaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Amaia LujambioDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Sheng LiThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Scott W LoweCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Joshua T MendellDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Venkat S MalladiBioinformatics Core Facility of the Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address: sawyersc@mskcc.org.
Ping MuDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Hamon Center for Regenerative Science and Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: ping.mu@utsouthwestern.edu.
Memorial Sloan Kettering Cancer Center · USSouthwestern Medical Center · USCornell University · USHoward Hughes Medical Institute · USIcahn School of Medicine at Mount Sinai · USJackson Laboratory · USLudwig Cancer Research · USRockefeller University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0MShared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MThe intersection of RNA biology and tumor biologyR35CA197311 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MENDELL, JOSHUA T · 2015 to 2021
$5.1MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MUnderstanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8MThe Spatiotemporal Landscape of the Human Brain EpitranscriptomeR01MH117406 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI MASON, CHRISTOPHER EDWARD · 2018 to 2022
$3.3MOvercome the lineage plasticity conferred targeted therapy resistance in advanced prostate cancerR00CA218885 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MU, PING · 2018 to 2020
$719kOvercome the lineage plasticity conferred targeted therapy resistance in advanced prostate cancerK99CA218885 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MU, PING · 2017 to 2017
$146kHoward Hughes Medical InstituteHoward Hughes Medical Institute DT0712NCATS NIH HHS UL1 TR001866NCI NIH HHS F99 CA223063NCI NIH HHS K99 CA218885NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA034196NCI NIH HHS P50 CA092629NCI NIH HHS R00 CA218885NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA193837NCI NIH HHS R35 CA197311NCI NIH HHS U54 CA224079NIH HHS U54 OD020355NIMH NIH HHS R01 MH117406
Abstract
Metastatic prostate cancer is characterized by recurrent genomic copy number alterations that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss as a cause of antiandrogen resistance in an in vivo small hairpin RNA (shRNA) screen of 730 genes deleted in prostate cancer. ATAC-seq and RNA-seq analyses showed that CHD1 loss resulted in global changes in open and closed chromatin with associated transcriptomic changes. Integrative analysis of this data, together with CRISPR-based functional screening, identified four transcription factors (NR3C1, POU3F2, NR2F1, and TBX2) that contribute to antiandrogen resistance, with associated activation of non-luminal lineage programs. Thus, CHD1 loss results in chromatin dysregulation, thereby establishing a state of transcriptional plasticity that enables the emergence of antiandrogen resistance through heterogeneous mechanisms.
Indexed as
Androgen AntagonistsAnimalsApoptosisBiomarkers, TumorCell ProliferationChromatinDNA-Binding ProteinsDNA HelicasesDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHigh-Throughput Screening AssaysHumansMaleMiceProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAndrogen AntagonistsAR protein, humanBiomarkers, TumorCHD1 protein, humanChromatinDNA-Binding ProteinsDNA HelicasesReceptors, AndrogenRNA, Small InterferingTranscription Factorsantiandrogen resistantcecastration-resistant prostate cancerCHD1chromatin remodelinglineage plasticityNR2F1NR3C1 (GR)POU3F2 (BRN2)TBX2tumor heterogeneity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.